Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Reports of anaphylactic-type reactions, including fatalities, following the administration of Dexferrum (iron dextran injection, USP) used to treat anemia or “iron-poor” blood in people who are unable to take oral iron medication, has spurred American Regent, Inc., makers of the drug, to modify the medicine’s black box warning, and the Food and Drug Administration (FDA) to issue a warning to hematological health care professionals and hospital risk managers.

Read the rest of this entry »